Objective:To compare therapeutic effects and safety of intracoronary (IC ) abciximab and intravenous (IV) abciximab on ST‐elevation myocardial infarction (STEMI) . Methods:The databases of PubMed ,Cochrane Central Register of Controlled Trials ,Chinese Biomedical Literature Database (CBM) and CNKI were retrieved on computers for collecting randomized controlled trials (RCTs) about comparison of therapeutic effects between IC abciximab and IV abciximab published from Jan 1993 to Jun 2014. At the same time ,the data included literature , conference abstracts and related websites were retrieved manually .The data of eligible RCTs were extracted and re‐ceived meta‐analysis using RevMan5.0 software .Results:A total of seven RCTs were enrolled .Meta‐analysis indi‐cated that incidence rate of recurrent myocardial infarction in IC abciximab group was significantly lower than that of IV abciximab group (OR= 0.61 ,95% CI:0.40~0.92 , P=0.02 );there were no significant difference in all‐cause mortality (OR=0.85 ,95% CI :0.59~1.23 ,P=0.39) ,target vessel revascularization rate (OR=0.66 ,95%CI :0.40~1.09 , P=0.10) and incidence rate of major bleeding (OR=1.00 ,95% CI :0.68~1.47 , P=0.99) be‐tween IC abciximab group and IV abciximab group . Conclusion:The IC abciximab can more significantly reduce in‐cidence rate of recurrent myocardial infarction in STEMI patients .

Objective: To explore the correlation of plasma level N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with non-diabetic acute myocardial infarction (AMI) combining stress hyperglycemia.
Methods: A total of 327 non-diabetic AMI patients treated in our hospital from 2012-02 to 2014-05 were studied. The patients were divided into 2 groups according to fasting blood glucose level:Stress group, the patients with blood glucose≥7.0 mmol/L, n=182 and Non-stress group, the patients with blood glucose<7.0 mmol/L, n=145. The basic clinical condition, laboratory tests within 24 hours of onsets, echocardiography and 24 h dynamic electrocardiogram were examined;the incidence of major adverse cardiovascular events (MACE) including arrhythmia, heart failure, cardiac shock and sudden cardiac death in 2 weeks of onsets were analyzed and compared between 2 groups.
Results: The patients’ age, gender, history of hypertension, smoking, drinking, and blood levels of TC, TG, HDL-C, LDL-C were similar between 2 groups, P>0.05. Plasma levels of NT-proBNP, CK-MB, MYO, ultra-TnI, ALT, AST and blood glucose level were signiifcantly different between 2 groups P<0.01. NT-proBNP level was positively related to
ultra-TnI (r2=0.811, r=0.901, P<0.01). Stress group presented obviously higher incidence of MACE (P<0.05), lower LVEF (P<0.01), and signiifcantly increased left ventricular end diastolic diameter, left ventricular end systolic diameter (P<0.01) than those in Non-stress group.
Conclusion: Plasma levels of NT-proBNP may judge the severity and evaluate recent prognosis in patients with non-diabetic AMI combining stress hyperglycemia, it could be used as a risk indicator for relevant patients in clinical practice.